Lucentis® Vial for Intravitreal Injection (10 mg/mL)

What Lucentis® Is and How It Works

Lucentis Vial contains ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor used by retina specialists. It treats neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Lucentis is given as an intravitreal injection in a clinic. Some customers ask about Lucentis Vial without insurance; pricing depends on dose and quantity prescribed.

Lucentis binds VEGF-A and reduces abnormal blood vessel growth and leakage in the retina. This helps reduce retinal fluid and can improve or maintain visual acuity when dosed regularly. The vial is a single-use presentation at 10 mg/mL. Dosing volume for most indications is 0.05 mL drawn under sterile technique, as directed by the treating physician.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies.

Your ophthalmology team determines the dosing plan. Many patients start with monthly injections, then move to a treat-and-extend or as-needed schedule guided by imaging and vision tests.

Dosage and Usage

• Initiation: Injections are administered by an eye care professional under aseptic conditions. Many patients begin with one injection every month.
• Maintenance: After the initial phase, schedules may shift to treat-and-extend or as-needed dosing to maintain fluid control and vision.
• Typical dose: 0.5 mg (0.05 mL) withdrawn from the vial for most indications. The exact regimen is set by the retina specialist.
• Injection route: Intravitreal only. Do not use intravenously or subcutaneously.
• Missed dose: If an injection is missed, the clinic schedules the next dose as soon as feasible.
• Clinical monitoring: IOP checks and retinal imaging guide ongoing timing.
• Device steps: The vial is single-use. The provider prepares the dose with sterile supplies and discards any remainder.

• Refrigerated storage: After delivery, place the vial in a refrigerator at 2–8°C (36–46°F). Do not freeze.
• Protect from light: Keep the vial in the original carton until your appointment.
• Handling: Do not shake. Keep upright and avoid excessive agitation.
• Short trips: For transport to your clinic, use an insulated bag with cool packs. Do not place the vial directly on ice.
• Room temperature window: If removed from refrigeration for a short period, avoid heat and return to 2–8°C promptly.
• Travel planning: Confirm your appointment time before travel. Bring your invoice and prescription copy if requested by the clinic.
• Shipping: Orders are packed with prompt, express, cold-chain shipping to help maintain temperature.

Benefits and Savings

Lucentis reduces retinal fluid, stabilizes neovascular activity, and can improve vision when dosed on schedule. Many patients see reduced injection burden over time with treat-and-extend plans guided by clinical response. The single-use vial supports precise dosing in clinic settings.

Many customers save 60–80% vs typical U.S. prices. If you are paying Lucentis Vial without insurance, you can request a quote based on your prescribed quantity.

We work with licensed, vetted partner pharmacies to supply authentic brand medications, with a broad selection and value-focused pricing.

See our promotions page for current offers, including any Lucentis Vial coupon if available.

Side Effects and Safety

• Common: conjunctival hemorrhage, eye pain or irritation, vitreous floaters, increased intraocular pressure (IOP) shortly after injection, transient blurred vision, tearing.
• Less common: intraocular inflammation, corneal abrasion, eyelid swelling, vision fluctuations, headache.
• Serious (seek urgent evaluation): endophthalmitis, retinal detachment, retinal tear, traumatic cataract, sustained IOP elevation, arterial thromboembolic events.
• Contraindications: ocular or periocular infection, active intraocular inflammation, known hypersensitivity to ranibizumab or formulation components.
• Drug interactions: systemic interactions are uncommon with intraocular dosing; the treating clinician reviews your medication list.

Serious complications are uncommon but can threaten vision. Prompt evaluation is required if you experience worsening eye pain, increasing floaters, sensitivity to light, or sudden vision changes after an injection. The clinic monitors IOP and retinal status to reduce risks.

Onset Time

Fluid reduction in the macula often appears within days to weeks on optical coherence tomography. Many patients experience early vision gains in the first 1–2 months. Continued dosing helps consolidate improvements and maintain vision over 3–6 months and beyond. Long-term outcomes depend on the underlying condition, adherence to the schedule, and response on imaging.

Compare With Alternatives

Lucentis is one of several anti-VEGF options. Eylea® (aflibercept) offers 2 mg dosing, with many regimens extending to every 8 weeks or longer after loading. Some clinics prefer Eylea for specific imaging patterns or when a longer interval is feasible. You can review details on Eylea.

Beovu® (brolucizumab) is another option designed to extend intervals in some responders. It has distinct efficacy and safety considerations, including intraocular inflammation risk that clinics monitor closely. For format options, see the Beovu Pre Filled Syringe.

Some practices also choose a prefilled syringe presentation of ranibizumab for workflow preferences. To compare formats, view the Product Lucentis Prefilled Syringe.

Combination Therapy

• Anti-VEGF plus focal/grid laser may be considered in select DME or BRVO cases under specialist guidance.
• Photodynamic therapy can be used for certain choroidal neovascular lesions when appropriate.
• Clinics typically avoid giving two anti-VEGF agents on the same day.
• Systemic antiplatelet or anticoagulant therapy is usually continued as prescribed by the managing physician.
• Follow the retina specialist’s plan for imaging, intervals, and adjunctive treatments.

Patient Suitability and Cost-Saving Tips

Lucentis may be appropriate for adults with neovascular AMD, DME, macular edema from RVO, or mCNV. It is not used in eyes with active infection or active intraocular inflammation. Caution is used in patients with recent thromboembolic events. Pregnancy and breastfeeding require individualized risk assessment by the provider.

To reduce overall costs, consider ordering multi-month quantities when your prescription and clinic schedule allow. Plan ahead for appointments so your supply arrives in time. Set a calendar reminder for reorders. Your clinic can advise whether the vial or a prefilled format aligns with its workflow.

Authoritative Sources

Genentech Lucentis Prescribing Information (U.S.)

Health Canada Drug Product Database: Lucentis (ranibizumab)

FDA Full Prescribing Information and Medication Guide

Order Lucentis® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This page is for educational purposes and is not a substitute for professional medical advice. Always follow your eye care professional’s instructions for diagnosis, treatment, and follow-up.